These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 22964582)

  • 1. miRNA-34 prevents cancer initiation and progression in a therapeutically resistant K-ras and p53-induced mouse model of lung adenocarcinoma.
    Kasinski AL; Slack FJ
    Cancer Res; 2012 Nov; 72(21):5576-87. PubMed ID: 22964582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.
    Mullany LK; Fan HY; Liu Z; White LD; Marshall A; Gunaratne P; Anderson ML; Creighton CJ; Xin L; Deavers M; Wong KK; Richards JS
    Oncogene; 2011 Aug; 30(32):3522-36. PubMed ID: 21423204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small RNA combination therapy for lung cancer.
    Xue W; Dahlman JE; Tammela T; Khan OF; Sood S; Dave A; Cai W; Chirino LM; Yang GR; Bronson R; Crowley DG; Sahay G; Schroeder A; Langer R; Anderson DG; Jacks T
    Proc Natl Acad Sci U S A; 2014 Aug; 111(34):E3553-61. PubMed ID: 25114235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple cells-of-origin of mutant K-Ras-induced mouse lung adenocarcinoma.
    Sutherland KD; Song JY; Kwon MC; Proost N; Zevenhoven J; Berns A
    Proc Natl Acad Sci U S A; 2014 Apr; 111(13):4952-7. PubMed ID: 24586047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer.
    Tan X; Carretero J; Chen Z; Zhang J; Wang Y; Chen J; Li X; Ye H; Tang C; Cheng X; Hou N; Yang X; Wong KK
    PLoS One; 2013; 8(11):e80885. PubMed ID: 24260500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.
    Okayama H; Saito M; Oue N; Weiss JM; Stauffer J; Takenoshita S; Wiltrout RH; Hussain SP; Harris CC
    Int J Cancer; 2013 Jan; 132(1):9-18. PubMed ID: 22618808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protein kinase Cα suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGFβ signaling axis.
    Hill KS; Erdogan E; Khoor A; Walsh MP; Leitges M; Murray NR; Fields AP
    Oncogene; 2014 Apr; 33(16):2134-44. PubMed ID: 23604119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thyroid transcription factor-1-regulated microRNA-532-5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells.
    Griesing S; Kajino T; Tai MC; Liu Z; Nakatochi M; Shimada Y; Suzuki M; Takahashi T
    Cancer Sci; 2017 Jul; 108(7):1394-1404. PubMed ID: 28474808
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
    Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
    J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.
    Elsum IA; Yates LL; Pearson HB; Phesse TJ; Long F; O'Donoghue R; Ernst M; Cullinane C; Humbert PO
    Oncogene; 2014 Nov; 33(48):5523-33. PubMed ID: 24276238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
    Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
    Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination wt-p53 and MicroRNA-125b Transfection in a Genetically Engineered Lung Cancer Model Using Dual CD44/EGFR-targeting Nanoparticles.
    Talekar M; Trivedi M; Shah P; Ouyang Q; Oka A; Gandham S; Amiji MM
    Mol Ther; 2016 Apr; 24(4):759-69. PubMed ID: 26686386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression.
    Okada N; Lin CP; Ribeiro MC; Biton A; Lai G; He X; Bu P; Vogel H; Jablons DM; Keller AC; Wilkinson JE; He B; Speed TP; He L
    Genes Dev; 2014 Mar; 28(5):438-50. PubMed ID: 24532687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Restoration of mutant K-Ras repressed miR-199b inhibits K-Ras mutant non-small cell lung cancer progression.
    Jin H; Jang Y; Cheng N; Li Q; Cui PF; Zhou ZW; Jiang HL; Cho MH; Westover KD; Tan QY; Xu CX
    J Exp Clin Cancer Res; 2019 Apr; 38(1):165. PubMed ID: 30987652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS.
    Qiu W; Tang SM; Lee S; Turk AT; Sireci AN; Qiu A; Rose C; Xie C; Kitajewski J; Wen HJ; Crawford HC; Sims PA; Hruban RH; Remotti HE; Su GH
    Gastroenterology; 2016 Jan; 150(1):218-228.e12. PubMed ID: 26408346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.
    Cho HC; Lai CY; Shao LE; Yu J
    Cancer Res; 2011 Dec; 71(23):7250-8. PubMed ID: 22088965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction.
    Fortunato O; Boeri M; Moro M; Verri C; Mensah M; Conte D; Caleca L; Roz L; Pastorino U; Sozzi G
    Cell Death Dis; 2014 Dec; 5(12):e1564. PubMed ID: 25501825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transgenic mouse model expressing P53(R172H), luciferase, EGFP, and KRAS(G12D) in a single open reading frame for live imaging of tumor.
    Ju HL; Calvisi DF; Moon H; Baek S; Ribback S; Dombrowski F; Cho KJ; Chung SI; Han KH; Ro SW
    Sci Rep; 2015 Jan; 5():8053. PubMed ID: 25623590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.).
    Wang IC; Ustiyan V; Zhang Y; Cai Y; Kalin TV; Kalinichenko VV
    Oncogene; 2014 Nov; 33(46):5391-6. PubMed ID: 24213573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.